Market Insight - UCL Business tackling pharma's university challenge
This article was originally published in Scrip
The pharmaceutical industry's productivity crisis is forcing companies to look further upstream for opportunities to tie up early-stage IP. For many firms this means doing deals on leading universities' territory. Academic institutions are learning to leverage their relationships with pharma as well. UCL Business, a wholly owned subsidiary of University College London, is doing deals to bring university assets closer to market with one ultimate goal: to deliver patient benefit, discovers Pete Chan.